_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
76 of 180 long COVID-associated genes also linked to ME
MRI is particularly valuable in pediatric care due to its non-invasive nature
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Growing patent filings and tier-2 innovators reflect expanding national research base
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Subscribe To Our Newsletter & Stay Updated
